上皮细胞专用培养基由abiowell技术团队精心筛选验证,经过长期测试,本产品可保持上皮细胞最佳的生长状态。本产品中已包含上皮细胞生长所需的各种成分,无需额外添加任何成分,可直接用上皮细胞的体外培养。
培养基成分 | 上皮细胞基础培养基+1%上皮细胞添加剂+2%FBS+1%双抗 |
细菌检测 | 阴性 |
真菌检测 | 阴性 |
支原体检测 | 阴性 |
细胞生长试验效果 | 形态正常,生长良好 |
运输条件 | 冰袋冷藏运输 |
存储条件 | 2℃-8℃,避光储存 |
有效期 | 6个月 |
供应限制 | 仅供科研使用 |
参考文献 (1)
Objective Oral squamous cell carcinoma (OSCC) has a poor prognosis and high mortality. This study aims to investigate the potential molecular mechanisms of NFIC/DEPTOR/mTOR signaling in glycolysis and tumor immune escape in OSCC. Design In vitro , the effects of the NFIC/DEPTOR/mTOR axis on the proliferative capacity and apoptosis of HN30 and SCC-25 cells were investigated using colony formation assays, EdU staining, and TUNEL after lentiviral gene interference. The glycolytic activity of OSCC cells was analyzed through glucose uptake, ECAR, and lactate production. CD8 + T cells were co-cultured with OSCC cells to analyze the cytotoxic activity of CD8 + T cells. SCC-25 cells with different genetic interventions were injected subcutaneously into NOG mice to investigate the effects of NFIC/DEPTOR/mTOR on subcutaneous tumor growth, tumor microenvironment (TME) acidity, and CD8 + T cell infiltration and activity. ChIP-qPCR and dual-luciferase assays were used to investigate the regulatory relationship between NFIC and the DEPTOR promoter in OSCC cells. Results NFIC and DEPTOR were significantly downregulated in OSCC cells and tissues, accompanied by enhanced mTOR signaling. NFIC activated DEPTOR by binding to its promoter. Overexpression of either NFIC or DEPTOR significantly inhibited OSCC cell proliferation, glycolytic activity, and enhanced CD8 + T cell killing capacity. Similarly, they inhibited tumor growth in vivo , blocked TME acidification, and weakened tumor immune escape. Combined DEPTOR knockdown rescued the malignant progression of OSCC inhibited by NFIC overexpression. Conclusion NFIC mediates DEPTOR transcription to repress mTOR signaling, thereby hindering OSCC progression by suppressing cell proliferation, glycolytic activity, and CD8 + T cell-related immune escape.















